European Commission Approves AbbVie's AQUIPTA for Acute Migraine Treatment
ABBV sits 19% above its 52-week low of $181.73.
Summary
The European Commission has approved AbbVie's AQUIPTA (atogepant) for the acute treatment of migraine in adults. This expands the drug's label in the EU, where it was already approved for migraine prevention, and follows other recent positive regulatory developments for AbbVie's portfolio. The approval is based on strong Phase 3 data showing fast and sustained pain relief. This new indication significantly broadens the addressable market for AQUIPTA in Europe, targeting a prevalent and debilitating condition with substantial economic impact.
At the time of this announcement, ABBV was trading at $216.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $376.2B. The 52-week trading range was $181.73 to $244.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.